Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

By sjmartinez • February 1, 2023

Dougados M, Charles-Schoeman C, Szekanecz Z, Giles JT, Ytterberg SR, Bhatt DL, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Connell CA, Yndestad A, Rivas JL, Buch MH. Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Jan 31:ard-2022-223406. doi: 10.1136/ard-2022-223406. Epub ahead of print. PMID: 36720582.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Frimodt-Møller[...]

Artificial Intelligence in Patch Testing: Comprehensive Review of Current Applications and Future Prospects in Dermatology

Tang HS, Ebriani J, Yan MJ, Wongvibulsin S, Farshchian M. Artificial Intelligence in Patch Testing: Comprehensive Review of Current Applications and Future Prospects in Dermatology.[...]

Author Correction: Dietary fiber content in clinical ketogenic diets modifies the gut microbiome and seizure resistance in mice

Özcan E, Yu KB, Dinh L, Lum GR, Lau K, Hsu J, Arino M, Paramo J, Lopez-Romero A, Hsiao EY. Author Correction: Dietary fiber content[...]